Given c-Met’s ability to promote tumor cell motility, invasion and resistance to EGFR-TKIs, c-Met inhibition has been hypothesized to limit tumor spreading and resistance to cytotoxic agents and targeted therapies.152. This evidence concerns the gene EGFR and neoplasm.